Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 1, 2013
Event: Entry into a Material Definitive Agreement (Item 1.01) and Regulation FD Disclosure (Item 7.01).
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. Key financial terms of the agreement include:
- Upfront Payment: $7,000,000 received immediately upon signing.
- Potential Milestone Payments: Up to an additional $7,000,000 contingent on meeting specific research and development milestones.
- Future Revenue Potential: License fees and annual royalties payable if the counterparty exercises its option to enter a Commercial Agreement.
- Agreement Term: Up to four (4) years for the Research Agreement.
Note: The filing does not provide data on the company's overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Agreement Structure
On October 1, 2013, 22nd Century Limited, LLC (a wholly-owned subsidiary) entered into a Research License and Commercial Option Agreement with British American Tobacco (Investments) Limited ("BAT").
- Licensing Rights: BAT received an exclusive worldwide license to certain patent and intellectual property rights for a defined field of use for up to four years.
- Commercial Option: BAT holds an option to obtain an exclusive worldwide license to commercialize products derived from the licensed IP.
- Collaboration: Both parties agreed to collaborate while conducting independent research.
- Reciprocal License: BAT granted the Company a worldwide license to any registered research results developed by BAT under the agreement, on commercially reasonable terms.
Outlook, Risks, and Contingencies
Management Commentary: The Registrant executed the agreement to guarantee the obligations of its subsidiary. A press release was issued simultaneously to disclose the material event.
Contingencies and Risks:
- Termination: BAT may terminate the agreement at any time, subject to specific payment requirements upon termination. The Company may terminate only in the event of certain uncured breaches.
- Uncertainty of Future Payments: The additional $7,000,000 and future royalties are contingent on BAT meeting milestones and exercising its commercial option.
- Documentation: The full text of the Research Agreement is not included in this filing but will be filed in the Annual Report on Form 10-K for the year ending December 31, 2013.
Investor Verification Checklist
- Verify the exact definition of the "field of use" and the specific milestones required to trigger the additional $7,000,000 payment.
- Review the full Research Agreement (to be filed in the 2013 Form 10-K) for detailed termination clauses and payment schedules.
- Confirm the accounting treatment of the $7,000,000 upfront payment (e.g., immediate revenue recognition vs. deferred revenue) in upcoming financial statements.
- Assess the strategic value of the reciprocal license granted by BAT to the Company.